For what it's worth I personally don't think a $1 USD financing is all that unreasonable when it puts the enterprise value of our ph 1 company at roughly $125 million USD (pretty much on par with the sad market cap for ph 3 RVX). A few things I consider when assessing this are that; Zenith seems relatively fairly valued compared to other phase 1's; the $1/share represents an increased valuation over the last $1/share financing due to dilution (the implied enterprise value continues to increase with each financing even though our individual shareholdings are diluted); from an implied return perspective, TD Waterhouse put about about a 16 cent/share CAD adjusted cost base on my Zenith shares at the time of the split, now that they are apparently worth about $1.30 CAD. That doesn't seem too bad. I do think we will only begin to get to the real truth when we see some ph 1 results and perhaps get an exchange listing and/or a spin off deal for one of Zeniths' compounds. That being said if we do get a public listing I fear we might experience a massive liquidation event due to pent up shareholder frustration resulting from managements inability to share both the Zenith and RVX stories effectively. I hope if we do get a listing it is on a US exchange and comes with first rate analyst coverage from the outset. Definitely not the BS coverage RVX has. Further, I think if ph 1 results are positive, that is when we should expect a real bump in enterprise value.